Self-reported loss of smell and taste in SARS-CoV-2 patients: primary care data to guide future early detection strategies

CURRENT STATUS: Posted

Benoit Tudrej, Paul Sebo, Julie Lourdaux, Clara Cuzin, Martin Floquet, Dagmar M Haller, Hubert Maisonneuve

Benoit Tudrej
University College of General Medicine, University Claude Bernard Lyon 1
✉ dr.tudrej@gmail.com Corresponding Author
ORCiD: https://orcid.org/0000-0003-3539-1833

Paul Sebo
Primary Care Unit, Faculty of medicine, University of Geneva

Julie Lourdaux
Cerballiance Rhône-Alpes Laboratory

Clara Cuzin
University College of General Medicine, University Claude Bernard Lyon 1

Martin Floquet
University College of General Medicine, University Claude Bernard Lyon 1

Dagmar M Haller
Primary Care Unit, Faculty of medicine, University of Geneva

Hubert Maisonneuve
Primary Care Unit, Faculty of medicine, University of Geneva
Subject Areas

*General Practice*  *Infectious Diseases*

Keywords

*smell and taste disorders, COVID-19, SARS-CoV2, RT-PCR, primary care*
Abstract

The early identification of new cases of SARS-CoV-2 infection in primary care is of outmost importance in the current pandemic. We conducted a preliminary study involving 816 primary care patients undergoing RT-PCR testing for a suspicion of COVID-19. We examined the association between smell or taste disorders and a positive SARS-CoV-2 test, and computed the performance of these symptoms in predicting a positive test. Smell or taste disorders were significantly associated with positive RT-PCR with an adjusted OR=6.3 (95%CI 5.2-7.5). Once confinement measures are lifted, our data could further inform triage and early identification of new clusters of cases through primary care.

Introduction

While initial reports did not highlight such symptoms, recent data from several countries suggest that SARS-CoV–2-positive inpatients experienced loss of smell and/or taste.(1,2) In a retrospective web-based study of outpatients who had attended one of three emerging diseases center in France, the combination of hyposmia and hypogeusia had moderate sensitivity (42%) and high specificity (95%) for the identification of SARS-CoV–2 positive patients.(2) Whilst loss of smell or taste could be a key symptom to guide early identification of new cases in primary care, the extent to which participants in this study were representative of primary care patients is unclear. To address this limitation, we conducted a study involving primary care patients in France.

Methods

This preliminary cross-sectional study was conducted between March 24th, 2020 and April 14th, 2020 in two clinical laboratories in Lyon (France) to which general practitioners (GPs) refer patients with a suspicion of COVID–19 for a nasopharyngeal smear (RT-PCR).

Before undergoing the test, patients responded to a pre-formatted questionnaire about their symptoms, built on previous literature (3,4) and expert opinion. Data were analyzed using Stata 15, adjusting for clustering within the two laboratories. We examined the univariate and multivariate association between smell and/or taste disorders and a positive SARS-CoV–2 test, adjusting for all the other symptoms frequently reported by the patients. We also examined the performance of these smell and taste symptoms in predicting a SARS-CoV–2 positive test.

Results

816 consecutively recruited patients were included in the analysis; 532 (65%) were women. The median age was 45 (interquartile range: 28, min-max: 4–92); 302 (37%) were healthcare professionals. Cough and dry throat were the most frequently reported symptoms (Table 1). Patients who tested positive for SARS-CoV–2 (n = 198 (24%)) reported loss of smell or taste significantly more often than patients who tested negative (Table 2). Smell or taste disorders were significantly associated with positive RT-PCR with an adjusted OR = 6.3 (95%CI 5.2–7.5) in this primary care population with a high pre-test probability of COVID–19.

Discussion

The tropism of SARS-CoV–2 for the nerves of the ear, nose and throat system (5) may explain the relatively high proportion of SARS-CoV–2 patients suffering from smell and taste disorders, compared to patients suffering from upper respiratory tract infections with other viruses.
In this epidemic context, a simple clinical screening tool could be very efficient. Smell and taste disorders seem to be very specific to SARS-CoV-2 infection. This is a key finding to inform triage strategies and early isolation of new clusters of infection through primary care. The high specificity of these symptoms mean GPs could rely on them to affirm a diagnosis of COVID-19, referring only patients with low pre-test probability (i.e. with non-specific symptoms) to RT-PCR screening. This could be a strategy to consider in lower resource settings, when RT-PCR testing is not widely available, or lack of protective gear would lead to excessive risk of contamination for the caregiver performing the test.

Our study was initiated after the first media reports of a possible link between anosmia and COVID-19. This may have prompted patients to over-report these symptoms, thus affecting their prevalence in our sample. Since patients were asked about the symptoms before receiving the results of their test, this limits the repercussions of this potential reporting bias on our measures of association.

Future studies should explore the diagnostic performance of various combinations of symptoms (i.e. anosmia and ageusia, anosmia without rhinitis, anosmia with nasal dryness...) to increase the specificity of the clinical picture. In accordance with Winants et al.’s recommendations, (6) these studies should be performed with a representative dataset (i.e. primary care based sample), an adequate description of the study population and external validation of the diagnostic tool.

In conclusion, our study shows that smell and taste disorders are common in primary care patients with SARS-CoV-2 infection. These symptoms might represent the first step to build a relatively simple clinical screening tool to use in primary care in an epidemic context. Once confinement measures are lifted, our data could further inform triage and early identification of new clusters of cases through primary care.

Declarations

Consent

Before responding to the questionnaire, all patients provided oral consent for their anonymous data to be used for research purposes.

The research protocol has been approved by the ethics committee of CNGE (Collège National des Généralistes Enseignants).

Acknowledgements

We thank all patients who accepted to participate in this study. We also thank Rémy Boussageon, Maud Laprée, Edith Corbineau, Jean Pascal Fournier, Cerballiance Part-Dieu and Etats-unis laboratories’ teams, the Villon microbiology platform, Amir Moussa for their assistance and the Maisonneuve family for their support.

Contributions

Benoit Tudrej (BT), Hubert Maisonneuve (HM) and Julie Lourdaux (JL) conceptualized and designed the study.

Clara Cuzin (CC), Martin Floquet (MF), HM and JL designed and conducted the data collection.

Paul Sebo (PS) and Dagmar M. Haller (DH) performed the data analysis.

PS, DH, HM and BT contributed to the interpretation of the data.

PS, DH, HM and BT wrote the first draft of the manuscript, and all authors approved the final version for submission.

Conflict of interest

None
1. Giacomelli A, Pezziati L, Conti F, et al. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020.

2. Bénézit F, Le Turnier P, Declerck C, et al. Utility of hyposmia and hypogeusia for the diagnosis of COVID-19. Lancet Infect Dis. 2020.

3. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020.

4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020.

5. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;15:7264-75.

6. Wynants L, Van Calster B, Bonten MMJ, et al. Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal. BMJ. 2020;07;369:m1328.

### Tables

#### Table 1.

Proportion of symptoms reported by patients (N=816)

| Symptoms               | N (%) |
|------------------------|-------|
| Anosmia or hyposmia    | 156 (19.1) |
| Ageusia or hypogeusia  | 188 (23.0) |
| Fever                  | 366 (44.9) |
| Asthenia               | 115 (14.1) |
| Headache               | 359 (44.1) |
| Cough                  | 450 (55.2) |
| Dyspnea                | 143 (17.5) |
| Chest pain*            | 164 (20.1) |
| Myalgia                | 166 (20.3) |
| Diarrhea*              | 174 (21.4) |
| Dry nose*              | 173 (21.2) |
| Stuffy nose*           | 211 (25.9) |
| Dry throat*            | 384 (47.1) |
| Sore throat            | 54 (6.6) |

* Data missing for one patient

#### Table 2.

Association between smell and/or taste disorders, and positivity of the SARS-CoV-2 RT-PCR test
| Symptoms                        | Overall (N=816), n (%) | Patients with a positive test (N=198), n (%) | Patients with a negative test (N=618), n (%) | Crude OR (95%CI) |
|--------------------------------|------------------------|---------------------------------------------|---------------------------------------------|------------------|
| Smell disorder                 | 156 (19.1)             | 82 (41.4)                                   | 74 (12.0)                                   | 5.2 (4.3-6.3)    |
| Taste disorder                 | 188 (23.0)             | 92 (46.5)                                   | 96 (15.5)                                   | 4.7 (3.4-6.6)    |
| Smell and taste disorder       | 102 (12.5)             | 58 (29.3)                                   | 44 (7.1)                                    | 5.4 (2.9-10.1)   |
| Smell or taste disorder        | 242 (29.7)             | 116 (58.6)                                  | 126 (20.4)                                  | 5.5 (4.6-6.7)    |

1. univariate logistic regression (adjusted for clustering within labs)
2. multivariate logistic regression (adjusted for clustering within labs, gender, age group, and patient reporting of fever, asthenia, headache, cough, dyspnea, chest pain, myalgia, diarrhea, dry nose, stuffy nose, dry throat, sore throat)
3. Anosmia or hyposmia
4. Ageusia or hypogeusia